Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2672

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2672
---
 nominations committee and compensation committee may not consist entirely of independent directors and
such committees may not be subject to annual performance evaluations. Accordingly, under these circumstances, you will not have the same
protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq.

We
do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain
terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will
therefore be limited to the appreciation of their stock.

Our
principal stockholders and management own a significant percentage of our common stock and are able to exert significant control
over matters subject to stockholder approval.

Our
executive officers, directors and their affiliates and our principal stockholders beneficially hold, in the aggregate, approximately
75% of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring
stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of
our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

124

Our
issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans, employee stock
purchase plan or otherwise will dilute all other stockholders.

We
expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity
awards to employees, directors, and consultants under our stock incentive plans and employee stock purchase plan. We may also raise capital
through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies,
products, or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional
capital stock, including as a result of the exercise of any warrants to purchase shares of common stock, may cause stockholders to experience
significant dilution of their ownership interests and the per share value of our common